FindTrial
Sign In

Practice pattern study of fluids given during abdominal cancer surgeries

PractIce pattern of intraoperative fluid therapy in elective major gastrointestinal cancer surgeries in India (I-INFUSE)– A multicentre observational study - I-INFUSE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/04/052011
Enrollment
1000
Registered
2023-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C210- Malignant neoplasm of anus, unspecified Health Condition 2: C189- Malignant neoplasm of colon, unspecified Health Condition 3: C23- Malignant neoplasm of gallbladder Health Condition 4: C260- Malignant neoplasm of intestinal tract, part unspecified Health Condition 5: C259- Malignant neoplasm of pancreas, unspecified Health Condition 6: C19- Malignant neoplasm of rectosigmoidjunction Health Condition 7: C20- Malignant neoplasm of rectum Health Condition 8: C179- Maligna

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Sohan Lal Solanki
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients (18 years or older) posted for Elective Open or Laparoscopic or Robotic Surgeries. 2. ASA 1-3 patients 3. Patients posted for gastro-intestinal cancer surgeries (Colo-rectal surgeries, small-bowel surgeries, gastrectomy; pancreatic surgery including Pancreatoduodenectomy, Pylorus-preserving Pancreatoduodenectomy (PPPD or Whipples Procedure), distal pancreatico-splenectomy, Radical antegrade modular pancreatosplenectomy (RAMPS), Appleby procedures; Radical or Revision Cholecystectomy, Gastro-Intestinal Stromal Tumor (GIST) excision, Retroperitoneal sarcoma excision)

Exclusion criteria

Exclusion criteria: 1. Patients posted for liver resections 2. Patients posted for Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (CRS±HIPEC). 3. Expected Blood Loss equal to or more than 35 ml/kg body weight (half of total blood volume)

Design outcomes

Primary

MeasureTime frame
Amount of crystalloids and colloids administered during intraoperative period in major elective GI surgeries.Timepoint: Amount of crystalloids and colloids measured at the end of surgery.—

Secondary

MeasureTime frame
1. To study the type of fluids and blood products given intraoperatively, the incidence of postoperative complications, length of ICU, length of hospital stays and in-hospital and 30-day mortality in patients undergoing surgery for GI Malignancies. 2. To determine the perioperative factors having significant correlation with postoperative outcomes in patients undergoing surgery for GI Malignancies. Timepoint: From immediate postoperative period to upto 30 days after surgery—

Countries

India

Contacts

Public ContactSohan Lal Solanki

Tata Memorial Hospital, Mumbai

sohan.solanki@gmail.com9869253201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026